SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES AND EXCHANGE ACT OF 1934
Date of Report: April 5, 2000
(Date of earliest event reported)
OXiGENE, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-21990 13-3679168
- --------------------------- ----------------------- ----------------------
(State or other jurisdiction Commission File Number) (IRS Employer
of incorporation) Identification Number)
One Copley Place, Suite 602, Boston, Massachusetts 02116
- -------------------------------------------------- ------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 536-9500
Item 5. Other Materially Important Events
On April 5, 2000, the Registrant issued a press release, a copy of
which is attached hereto as Exhibit 99.1, announcing clinical results regarding
its lead tumor vascular targeting agent, Combretastatin A4 Prodrug, as presented
at the 91st Annual meeting of the Amercian Association for Cancer Research.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits.
99.1 Press release of the Registrant, dated April 5, 2000.
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned herewith duly authorized.
Date: April 6, 2000 OXiGENE, INC.
(Registrant)
By: /s/ Bo Haglund
-----------------------------
Bo Haglund
Chief Financial Officer
EXHIBIT INDEX
Exhibit
99.1 Press release of the Registrant, dated April 5, 2000.